ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2438

Reduction in Oral Corticosteroid Use During Anifrolumab Therapy: Observations from a Real-world Cohort of Adults with Systemic Lupus Erythematosus

Vasileios Kyttaris1, Gelareh Atefi2, Dan Persons3, Dana Withrow3 and Mawuena Binka4, 1BIDMC, Boston, MA, 2AstraZeneca, Media, PA, 3Trio Health, Louisville, CO, USA, Louisville, 4BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE

Meeting: ACR Convergence 2024

Keywords: Biologicals, Cohort Study, corticosteroids, glucocorticoids, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: SLE – Treatment Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Oral corticosteroids (OCS) are a mainstay in the clinical management of systemic lupus erythematosus (SLE). However, prolonged use may result in systemic side effects.1 Thus, identifying therapies that effectively manage SLE while reducing OCS is vital. Clinical studies on first-in-class type I interferon inhibitor anifrolumab have shown a reduction in OCS dose and flares among SLE patients.2,3 In this study, we assess real-world OCS use before and during anifrolumab therapy among adults with SLE in the United States (US).

Methods: This retrospective, observational cohort study included data from patients with SLE in the American Rheumatology Network. Patients included were ≥18 years initiating anifrolumab (index date) from August 2, 2021 and followed until December 31, 2023, with ≥180 days of clinical history pre-index and ≥360 days of follow-up post-index, serum creatinine ≤2.0 mg/dL and urine protein-creatinine ratio ≤2.0 mg/mg. Participants received OCS at baseline and adhered to anifrolumab during follow-up (≥6 infusions from index to day 360 post-index). Outcomes assessed included: 1) OCS use (mean daily OCS dose [prednisone equivalents, PE] for days supplied, proportion of patients receiving OCS, and with mean daily OCS dose >5 mg or >7.5 mg); 2) clinical disease assessments (SLEDAI-2K, complement C3/C4). Outcomes were assessed during 180-day (6-month) periods at baseline (day -180 to -1 pre-index), and during follow-up (1-180 days post-index [Period 1], and 181-360 days post-index [Period 2]). The result closest to the end of each 180-day period was chosen per patient, with group estimates reported.

Results: The 69 participants on OCS therapy at baseline were mostly female (93%), white (52%), with median age 53 (IQR 43-59) years. [TABLE 1] An increasing number of patients discontinued OCS during follow-up (Period 1: n=15, 22%; Period 2: n=23, 33%). [TABLE 2] The mean total OCS dose per patient decreased from 772.15 mg at baseline to 743.64 (-4%) in Period 1 and 559.97 (-27%) in Period 2. Over time, fewer patients had mean daily OCS dose >5 mg (baseline: 57; Period 1: 42; Period 2: 32), and >7.5 mg (baseline: 44; Period 1: 35; Period 2: 28), with ≥20% reduction in mean daily dose for these high-dose OCS groups by Period 2 ( >5mg group: -20%; >7.5 mg group: -28%). [TABLE 2] Where available, median SLEDAI-2K scores also declined during follow-up (baseline: 10; Period 1: 8; Period 2: 6). [TABLE 3]

Conclusion: In this real-world cohort of patients with SLE on anifrolumab therapy, a reduction in OCS use was noted within the first six months of anifrolumab initiation. Treatment benefits increased with longer duration of anifrolumab therapy, with large reductions in the number of patients receiving high-dose OCS, OCS dose reduction among patients on high-dose OCS, and a third of patients discontinuing OCS by the end of year one. Decreased OCS use was accompanied by a decline in disease activity, as assessed with SLEDAI-2K. These findings provide real-world evidence of OCS sparing with anifrolumab therapy together with reduction in disease activity.

References:

1.      Frodlund M, et al. Rheumatology. 2024;63(4):1104-1112

2.      Furie R, et al. Lupus. 2021;30(8):1254-1263

3.      Kalunian K, et al. Arthritis Rheumatol. 2023;75(2):253-265

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: V. Kyttaris: AstraZeneca, 2, 12, Site PI, BMS, 12, Site PI for Clinical Trial, Fresenius Kabi, 1, Janssen, 1; G. Atefi: AstraZeneca, 3; D. Persons: AstraZeneca, 5, Trio Health, 3; D. Withrow: None; M. Binka: AstraZeneca, 3, 11.

To cite this abstract in AMA style:

Kyttaris V, Atefi G, Persons D, Withrow D, Binka M. Reduction in Oral Corticosteroid Use During Anifrolumab Therapy: Observations from a Real-world Cohort of Adults with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/reduction-in-oral-corticosteroid-use-during-anifrolumab-therapy-observations-from-a-real-world-cohort-of-adults-with-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/reduction-in-oral-corticosteroid-use-during-anifrolumab-therapy-observations-from-a-real-world-cohort-of-adults-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology